Cancer-associated thrombosis: Focus on extended therapy with dalteparin

Journal of Supportive Oncology

Volumn 4, Issue 3, 2006, Pages 115-119

  Bick, Rodger L ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; ERYTHROPOIETIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN; TAMOXIFEN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD VESSEL INJURY; CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; LONG TERM CARE; LUNG CANCER; LUNG EMBOLISM; MAXIMUM PERMISSIBLE DOSE; META ANALYSIS; MORBIDITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT FAILURE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DALTEPARIN; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 33645769496     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Trousseau A. Phlegmasia alba dolens. In:Clinique Medical de L'Hotel Dieu de Parins. Vol 3. London:The New Sydenham Society; 1865:94-98.
2. Bick RL. Cancer-associated thrombosis. N Engl J Med 2003;349:109-111.
3. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
4. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
5. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio:a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
6. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 1997;80:649-655.
7. Elkelboom JW, Baker RI. Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. Am J Hematol 1998;59:260-261.
8. Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001;111:270-273.
9. Elias EG. Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung. J Med 1974;5:114-132.
10. Thornes RD. Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer 1975;35:91-97.
11. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
12. Levine M. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. Semin Thromb Hemost 2003;29(suppl 1):9-11.
13. Ramzi DW, Leeper KV. DVT and pulmonary embolism: part II. treatment and prevention. Am Fam Physician 2004;69:2841-2848.
14. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):401S-428S.
15. Holzheimer RG. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Eur J Med Res 2004;9:225-239.
16. Petralia P, Kakkar AK. Antithrombotic therapy with low molecular weight heparin in cancer patients. Eur J Med Res 2004;9:119-124.
17. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 2004;22:1944-1948.
18. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192-197.
19. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131.
20. Johnson MJ. Bleeding, clotting and cancer. Clin Oncol (R Coll Radiol) 1997;9:294-301.
21. Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 1997;78:117-120.
22. von Tempelhoff GF, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997;77:456-461.
23. Vukovich TC, Gabriel A, Schaeffer B, et al. Hemostasis activation in patients undergoing brain tumor surgery. J Neurosurg 1997;87:508-511.
24. Mousa SA. Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev 2004;22:121-134.
25. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
26. van Der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000, 2002;CD002001.
27. Hillen HF. Thrombosis in cancer patients. Ann Oncol 2000;11(suppl 3):273-276.
28. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980;73:841-843.
29. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.
30. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
31. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism:a population-based cohort study. Arch Intern Med 2000;160:761-768.
32. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381-388.
33. Wong JE. Are patients with cancer receiving adequate treatment for thrombosis? results from FRONTLINE. Cancer Treat Rev 2003;29(suppl 2):11-13.
34. Deitcher SR. Dalteparin reduced recurrent venous thromboembolism more than oral anticoagulation in patients with cancer. ACP J Club 2004;140:10.
35. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995;74:1055-1058.
36. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698. Erratum in: N Engl J Med 1997;337:1567.
37. Hull RD, Pineo GE, Mah AF, et al. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 2000;96:449a [abstract].
38. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999;81:26-31.
39. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994;72:191-197.
40. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 2000;84:559-564.
41. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996;20:521-526.
42. Gonzalez-Fajardo JA, Arreba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 1999;30:283-292.
43. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events (VTE) in patients with active malignancy: a randomized study of enoxaparin sodium alone vs. initial enoxaparin sodium followed by warfarin for a 180-day period. J Thromb Haemost 2003;1(suppl 1):OC194.
44. Hull RD, Pineo GE, Mah AF, et al. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002;100:148a [abstract].
45. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism:examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
46. Blot E, Gutman F, Thannberger A. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med 2003;349:1385-1387; author reply 1385-1387.
47. Hull JH, Hull PJ. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med 2003;349:1385-1387; author reply 1385-1387.
48. Kaufman JL. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer. N Engl J Med 2003;349:1385-1387; author reply 1385-1387.
49. Lee A, Levine M. Letter to the editor: the authors reply. N Engl J Med 2003;349:1385.